MARKET

BLRX

BLRX

Biolinerx
NASDAQ
1.460
-0.030
-2.01%
After Hours: 1.560 +0.1 +6.85% 17:59 11/27 EST
OPEN
1.590
PREV CLOSE
1.490
HIGH
1.590
LOW
1.430
VOLUME
437.30K
TURNOVER
0
52 WEEK HIGH
2.530
52 WEEK LOW
0.5450
MARKET CAP
105.42M
P/E (TTM)
-1.7160
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BLRX last week (1120-1124)?
Weekly Report · 1d ago
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
Benzinga · 11/20 17:37
Bioline RX Receives Buy Rating Despite Lower Than Expected Q3 Results: Expansions, Partnerships, and Promising Clinical Trials Signal Future Growth
TipRanks · 11/20 17:35
Biolinerx: Report of foreign issuer
Press release · 11/20 14:01
LRHC, SGD and NSTG among pre-market losers
Syntec optics holdings (optx) -15%; plus therapeutics (pstv) reports new interim respect-gbm phase 2 trial data at the society for neurooncology annual meeting. Lrhc, sgd and nstg among pre-market losers.
Seeking Alpha · 11/20 13:24
Earnings Scheduled For November 20, 2023
Greenland technologies is projected to report quarterly earnings at $0.05 per share on revenue of $24.26 million. Techprecision is expected to report earnings for its second quarter. Agilent technologies is likely to report after the bell. Companies to report before the bell and after the bell.
Benzinga · 11/20 12:11
biolinerx GAAP EPS of -$0.01
As of september 30, 2023, we held $26.0 million of cash, cash equivalents and short-term bank deposits. We anticipate that this amount will be sufficient to fund operations into 2025. Biolinerx reported a q3 gaap eps of -$0.01.
Seeking Alpha · 11/20 12:03
BioLine Rx Q3 EPS $(0.01) May Not Be Comparable To $(0.21) Estimate
Benzinga · 11/20 12:02
More
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers BioLine RX Ltd - ADR stock information, including NASDAQ: BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.